Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma.


Journal

Journal of visualized experiments : JoVE
ISSN: 1940-087X
Titre abrégé: J Vis Exp
Pays: United States
ID NLM: 101313252

Informations de publication

Date de publication:
02 06 2023
Historique:
medline: 21 6 2023
pubmed: 19 6 2023
entrez: 19 6 2023
Statut: epublish

Résumé

Patient-derived xenograft (PDX) models faithfully preserve the histological and genetic characteristics of the primary tumor and maintain its heterogeneity. Pharmacodynamic results based on PDX models are highly correlated with clinical practice. Anaplastic thyroid carcinoma (ATC) is the most malignant subtype of thyroid cancer, with strong invasiveness, poor prognosis, and limited treatment. Although the incidence rate of ATC accounts for only 2%-5% of thyroid cancer, its mortality rate is as high as 15%-50%. Head and neck squamous cell carcinoma (HNSCC) is one of the most common head and neck malignancies, with over 600,000 new cases worldwide each year. Herein, detailed protocols are presented to establish PDX models of ATC and HNSCC. In this work, the key factors influencing the success rate of model construction were analyzed, and the histopathological features were compared between the PDX model and the primary tumor. Furthermore, the clinical relevance of the model was validated by evaluating the in vivo therapeutic efficacy of representative clinically used drugs in the successfully constructed PDX models.

Identifiants

pubmed: 37335092
doi: 10.3791/64623
doi:

Types de publication

Journal Article Video-Audio Media Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Maodi Wu (M)

Precision Medicine Research Center, Sichuan Provincial Key Laboratory of Precision Medicine, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University; Sichuan Kangcheng Biotech Co.

Yang Liu (Y)

Department of Thyroid Surgery, West China Hospital, Sichuan University.

Yi Zhao (Y)

Sichuan Kangcheng Biotech Co.

Yuyao Zhang (Y)

Sichuan Cancer Hospital.

Liansi Huang (L)

Sichuan Kangcheng Biotech Co.

Qijun Du (Q)

Sichuan Kangcheng Biotech Co.

Ting Zhang (T)

Precision Medicine Research Center, Sichuan Provincial Key Laboratory of Precision Medicine, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University; Sichuan Kangcheng Biotech Co.

Zhihui Zhong (Z)

Precision Medicine Research Center, Sichuan Provincial Key Laboratory of Precision Medicine, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University; Sichuan Kangcheng Biotech Co.

Han Luo (H)

Department of Thyroid Surgery, West China Hospital, Sichuan University.

Kai Xiao (K)

Precision Medicine Research Center, Sichuan Provincial Key Laboratory of Precision Medicine, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University; Sichuan Kangcheng Biotech Co.; xiaokaikaixiao@scu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH